Tamara Gracia‐Cazaña

Universidad de Zaragoza

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Yolanda Gilaberte

Hospital Universitario Miguel Servet

Alba Navarro‐Bielsa

Hospital Universitario Miguel Servet

Manuel Almenara‐Blasco

Hospital Universitario Miguel Servet

ÁJ

Ángeles Juarranz

Instituto Ramón y Cajal de Investigación Sanitaria

Salvador González

Universidad de Alcalá

Esteban Padgett

Centro de Salud Casa del Barco

I. Pastushenko

Hospital Clínico Universitario Lozano Blesa

S.E. Marrón

Hospital Universitario Miguel Servet

Pedro Gil‐Pallares

Hospital Universitario Miguel Servet

Isabel Abadías‐Granado

Centro de Salud Casa del Barco

Cooperative Institutions

Hospital Universitario Miguel Servet

Instituto de Investigación Sanitaria Aragón

Universidad de Zaragoza

Hospital Clínico Universitario Lozano Blesa

John Wiley & Sons (United States)

Spanish Academy of Dermatology and Venereology

Oxfam

John Wiley & Sons (United Kingdom)

Hospital General San Jorge

Centro de Salud Casa del Barco

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing

Clinical Cosmetic and Investigational Dermatology (2023)

Tamara Gracia‐Cazaña Laura Bernal-Masferrer Ana María Morales-Callaghan Manuel Almenara‐Blasco Yolanda Gilaberte

Abstract: Biologic treatments are increasingly being used in the management of moderate to severe plaque psoriasis (PSO). Risankizumab (RZB) is a humanized monoclonal antibody that specifically blocks the p19 subunit of interleukin 23, which in turn regulates the activation, differentiation, and survival of Th17. RZB has proved their efficacy and their safety compared to anti-TNF. However, studies that assess and compare the improvement in other secondary PROs such as the patient's quality of life are still scarce. Health-related quality of life (HRQoL) is the sum of physical health, well-being, and participation; it defines the functional effect of a disease or its treatment and how it is perceived by the patient. The objective of this paper is to analyze the literature on the impact of treatment with RZB on the quality of life of patients with PSO and their psychological well-being. A bibliographic search was carried out to identify all the papers published from July 2015 to June 1, 2022, on RZB treatment in psoriasis and its impact on health-related quality of life and psychological well-being, finally twenty articles have been evaluated in full text, of which 8 were excluded because they did not meet the inclusion criteria. Risankizumab has shown not only to have very relevant data on effectiveness and safety, but all of this is associated with an improvement in quality of life related to health and psychological well-being measured on generic and specific quality of life scales, both in pivotal trials, ad hoc analysis, and data in real clinical practice. Keywords: Risankizumab, health related quality of life, psoriasis

10.2147/ccid.s296544

Cite

Citations (4)

Sequential daylight photodynamic therapy and ingenol mebutate versus 2 sessions of daylight photodynamic therapy for the treatment of actinic keratosis: An observational, prospective, comparative study

Photodiagnosis and Photodynamic Therapy (2019)

Tamara Gracia‐Cazaña Ana Julia García Malinis Manuel Almagro-Sánchez Dolores Planas Linares Yolanda Gilaberte

Actinic keratosis

Daylight

Keratosis

10.1016/j.pdpdt.2019.05.030

Cite

Citations (3)

“Snail-Track Ulcers” And Macroglossia Due to Secondary Syphilis

Dermatology Practical & Conceptual (2023)

Alba Navarro‐Bielsa Tamara Gracia‐Cazaña Yolanda Gilaberte

Citation: Navarro-Bielsa A, Gracia-Cazaña T, Gilaberte Y. “Snail-Track Ulcers” And Macroglossia Due To Secondary Syphilis. Dermatol Pract Concept. 2023;13(4):e2023210. DOI: https://doi.org/10.5826/dpc.1304a210

Macroglossia

10.5826/dpc.1304a210

Cite

Citations (0)

Dermoscopic Structures Predictive of Response to Photodynamic Therapy in Basal Cell Carcinoma

Acta Dermato Venereologica (2023)

Alba Navarro‐Bielsa P.A. Cerro-Muñoz Manuel Almenara‐Blasco Tamara Gracia‐Cazaña Yolanda Gilaberte

Abstract is missing (Short communication)

Complete response

Basal (medicine)

10.2340/actadv.v103.4838

Cite

Citations (1)

Tumor microenvironment in non-melanoma skin cancer resistance to photodynamic therapy

Frontiers in Oncology (2022)

P.A. Cerro Marta Mascaraque María Gallego-Rentero Manuel Almenara‐Blasco Jimena Nicolás-Morala

Non-melanoma skin cancer has recently seen an increase in prevalence, and it is estimated that this grow will continue in the coming years. In this sense, the importance of therapy effectiveness has increased, especially photodynamic therapy. Photodynamic therapy has attracted much attention as a minimally invasive, selective and repeatable approach for skin cancer treatment and prevention. Although its high efficiency, this strategy has also faced problems related to tumor resistance, where the tumor microenvironment has gained a well-deserved role in recent years. Tumor microenvironment denotes a wide variety of elements, such as cancer-associated fibroblasts, immune cells, endothelial cells or the extracellular matrix, where their interaction and the secretion of a wide diversity of cytokines. Therefore, the need of designing new strategies targeting elements of the tumor microenvironment to overcome the observed resistance has become evident. To this end, in this review we focus on the role of cancer-associated fibroblasts and tumor-associated macrophages in the resistance to photodynamic therapy. We are also exploring new approaches consisting in the combination of new and old drugs targeting these cells with photodynamic therapy to enhance treatment outcomes of non-melanoma skin cancer.

Targeted Therapy

10.3389/fonc.2022.970279

Cite

Citations (7)

Photodynamic Therapy: Influence of Clinical and Procedure Variables on Treatment Response in Basal Cell Carcinoma and Bowen Disease

Acta Dermato Venereologica (2017)

Tamara Gracia‐Cazaña Marta Mascaraque N. Salazar Jesús Vera‐Álvarez María Pilar Frías

Bowen's disease

Complete response

10.2340/00015555-2756

Cite

Citations (8)

When Virtual Assistants Meet Teledermatology: Validation of a Virtual Assistant to Improve the Quality of Life of Psoriatic Patients

International Journal of Environmental Research and Public Health (2022)

Surya Roca Manuel Almenara‐Blasco Yolanda Gilaberte Tamara Gracia‐Cazaña Ana M. Morales Callaghan

Teledermatology has given dermatologists a tool to track patients’ responses to therapy using images. Virtual assistants, the programs that interact with users through text or voice messages, could be used in teledermatology to enhance the interaction of the tool with the patients and healthcare professionals and the overall impact of the medication and quality of life of patients. As such, this work aimed to investigate the effectiveness of using a virtual assistant for teledermatology and its impact on the quality of life. We conducted surveys with the participants and measured the usability of the system with the System Usability Scale (SUS). A total of 34 participants (30 patients diagnosed with moderate-severe psoriasis and 4 healthcare professionals) were included in the study. The measurement of the improvement of quality of life was done by analyzing Psoriasis Quality of Life (PSOLIFE) and Dermatology Life Quality Index (DLQI) questionnaires. The results showed that, on average, the quality of life improved (from 63.8 to 64.8 for PSOLIFE (with a p-value of 0.66 and an effect size of 0.06) and 4.4 to 2.8 for DLQI (with a p-value of 0.04 and an effect size of 0.31)). Patients also used the virtual assistant to do 52 medical consultations. Moreover, the usability is above average, with a SUS score of 70.1. As supported by MMAS-8 results, adherence also improved slightly. Our work demonstrates the improvement of the quality of life with the use of a virtual assistant in teledermatology, which could be attributed to the sense of security or peace of mind the patients get as they can contact their dermatologists directly within the virtual assistant-integrated system.

Teledermatology

System usability scale

Health Professionals

10.3390/ijerph192114527

Cite

Citations (3)

Resultados comunicados por el paciente, adherencia y satisfacción en pacientes con psoriasis

Actas Dermo-Sifiliográficas (2024)

Judit Perales Pascual Herminia Navarro Aznárez Avi Perez Tamara Gracia‐Cazaña Yolanda Gilaberte Calzada

ANTECEDENTES Y OBJETIVOS : Resultados comunicados por el paciente (PROs) hace referencia al resultado evaluado por el paciente y basado en la percepción de su enfermedad y tratamiento. El objetivo es determinar la adherencia, calidad de vida (CV) y satisfacción con el tratamiento antipsoriásico. MATERIAL Y METODOS: Estudio observacional-transversal, prospectivo y unicéntrico en el que se realizaron encuestas PROs sobre adherencia (test de Morisky-Green (MG)), satisfacción con el tratamiento (Cuestionario Español de Satisfacción de Tratamiento en Psoriasis(CESTEP)) y CV (Skindex-29 y DLQI). Otras variables: PASI, BSA. Análisis estadístico: Jamovi®2.3.26. RESULTADOS Se realizaron 100 encuestas. Del cuestionario MG se obtuvo que el 75%(75/100) eran pacientes adherentes y del registro de dispensaciones el 94%(94/100), del CESTEP se obtuvo una media de 7,4±7,7 (resultado cercano a la máxima satisfacción 0), del DLQI de 2,6±4,6 (pequeño efecto en la CV) y de SKINDEX-29 14,6±15,4 (68% afectación leve (<5) o muy leve (6-17) según interpretación de Nijsten et al). De CESTEP se obtuvo un valor de p.Rho Spearman en relación con el PASI en el momento del estudio de 0,338(p=0,004), con el BSA del 0,255(p=0,050), con el resultado del DLQI de 0,508(p<0,001) y del Skindex-29 0,397(p<0,001). De la matriz de correlación entre el resultado del DLQI y el PASI en el momento del estudio de 0,365(p=0,002) y de BSA de 0,347(p=0,007). El resultado de Skindex-29 con PASI fue de 0,380(p=0,001) y con BSA de 0,295(p=0,022). CONCLUSIONES: Los pacientes tratados presentan una buena CV, una alta adherencia y satisfacción al tratamiento. Existe una correlación significativa entre satisfacción, CV y PASI-BSA en el momento del estudio. BACKGROUND AND OBJECTIVES : Patient-reported outcomes (PROs) are outcomes evaluated by patients based on their perception of their disease and treatment. The objective of PROs is to determine antipsoriatic treatment-related adherence, quality of life (QoL) and satisfaction. MATERIALS AND METHODS: We conducted an observational cross-sectional, prospective, and single-center study in which PROs surveys were conducted on adherence (Morisky-Green [MG] test), treatment satisfaction (Spanish Questionnaire of Treatment Satisfaction in Psoriasis [CESTEP]) and QoL (Skindex-29 and DLQI). Additional variables include: PASI, BSA. Statistical analysis: Jamovi®2.3.26. RESULTS: A total of 100 surveys were conducted. Based on the MG questionnaire, we found that 75% (75/100) of patients were adherent vs 94% (94/100) from the dispensation records. Regarding CESTEP, a mean score of 7.4 ± 7.7 (close to maximum satisfaction 0) was obtained, while DLQI yielded a score of 2.6 ± 4.6 (indicating a small effect on QoL), and SKINDEX-29 a score of 14.6 ± 15.4 (68% indicating mild (< 5) or very mild (6-17) impact according to Nijsten et al.). Based on CESTEP a p.Rho Spearman value of 0.338 (p = 0.004) was obtained in relation to PASI when the study was conducted with a BSA of 0.255 (p = 0.050), DLQI results of 0.508 (p < 0.001) and Skindex-29 results of 0.397(p < 0.001). At the time of the study, the correlation matrix between DLQI result and PASI was 0.365 (p = 0.002) with a BSA of 0.347 (p = 0.007). Skindex-29 results with PASI were 0.380 (p = 0.001) and with BSA, 0.295 (p = 0.022). CONCLUSIONS: Patients on therapy exhibit a good QoL, high adherence and satisfaction with their treatment. A significant correlation was seen among satisfaction, QoL, and PASI-BSA at the time of the study.

10.1016/j.ad.2024.05.021

Cite

Citations (0)

Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.

Dermatology Online Journal (2019)

Tamara Gracia‐Cazaña Esteban Padgett Alba Hernández-García María Pilar Sánchez-Salas

Anti-programmed cell death (PD)-1 therapies in metastatic tumors have a high incidence of immune adverse events, including cutaneous manifestations such as vitiligo-like lesions. This side effect is associated with increased survival and it is a clinical marker of response to treatment. This case report is a graphic representation of the appearance of vitiligo-like lesions over in-transit metastases of malignant melanoma linked to a complete response to treatment with pembrolizumab.

Vitiligo

10.5070/d32512046728

Cite

Citations (2)

The Influence of the Exposome in the Cutaneous Squamous Cell Carcinoma, a Multicenter Case–Control Study

Cancers (2023)

Alba Navarro‐Bielsa Tamara Gracia‐Cazaña Manuel Almagro S. de la Fuente-Meira Ángeles Flórez

Introduction: The concept of exposome refers to the total of harmful and beneficial environmental exposures that can help predict the organism’s biological responses over time. Ultraviolet radiation (UVR) from sun exposure has been recognized as the main etiological agent of skin cancer, and squamous cell carcinoma (SCC) is one most commonly associated with chronic exposure. However, in recent years, evidence suggests that lifestyle, environmental pollution, and contaminants in water and food can have an influence. Objectives: To study the relationship between SCC and sun exposure, pollution, stress, and lifestyle in a Spanish cohort. Materials and Method: A multicenter case–control study was carried out in which 13 dermatologists from different regions of Spain recruited cases and controls between April 2020 and August 2022. The group of cases were patients diagnosed with SCC and, as a control group, people who attended Dermatology consultations as companions with no history of skin cancer. Results: A total of 62 patients with SCC and 126 controls were included (62.9% males, median age 76.46 (10.1) and 33.3%, median age 55.7 (15), respectively). The SCC group had experienced more outside work than the controls (75% vs. 22.4%, p < 0.001), less recreational exposure (sunbathing, p = 0.05, and outdoor sports, p = 0.01), and a lower annual income (p = 0.01), with an increase in tobacco exposure (p < 0.001), without differences in other carcinogens, such as ionizing radiation or chemical exposure. The control group had a higher daily screentime use (p < 0.001) and practiced more relaxation activities (p = 0.03). A higher linolenic acid intake and lower coffee consumption were the only dietary variables associated with SCC (p < 0.05). Some chronic medications (anxiolytics, antidepressants, beta-blockers, statins, hydrochlorothiazide, ACE inhibitors, metformin, and omeprazole) were also statistically associated with SCC. Statistical significance for all aforementioned variables was maintained in the multivariate analysis (p < 0.05). Conclusions: The study found a significant association between SCC and multiple exposome-related factors in addition to chronic sun exposure in the Spanish population. Primary prevention strategies should target specific populations, such as outdoor workers promoting sun-safe behaviors and stress-reducing activities, in addition to adequate skin photoprotection in patients under certain medications associated with SCC.

Sunbathing

Exposome

10.3390/cancers15225376

Cite

Citations (1)